KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBITDA (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBITDA data on record, last reported at -$40.3 million in Q4 2025.

  • For Q4 2025, EBITDA fell 3352.34% year-over-year to -$40.3 million; the TTM value through Dec 2025 reached -$546.3 million, down 76.44%, while the annual FY2025 figure was -$546.3 million, 76.44% down from the prior year.
  • EBITDA reached -$40.3 million in Q4 2025 per PACB's latest filing, down from -$37.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $16.6 million in Q3 2021 and bottomed at -$426.1 million in Q1 2025.
  • Average EBITDA over 5 years is -$82.9 million, with a median of -$71.7 million recorded in 2022.
  • The widest YoY moves for EBITDA: up 169.55% in 2021, down 6894.56% in 2021.
  • A 5-year view of EBITDA shows it stood at -$70.4 million in 2021, then decreased by 17.67% to -$82.9 million in 2022, then rose by 3.53% to -$80.0 million in 2023, then soared by 101.55% to $1.2 million in 2024, then plummeted by 3352.34% to -$40.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$40.3 million in Q4 2025, -$37.9 million in Q3 2025, and -$42.0 million in Q2 2025.